Prognosis with Parkinson's disease in Europe: A collaborative study of population-based cohorts

Neurology

Volumn 54, Issue 11 SUPPL. 5, 2000, Pages

  Berger, K ^e   Breteler, M M B ^a   Helmer, C ^b   Inzitari, D ^e   Fratiglioni, L ^e   Trenkwalder, C ^c   Hofman, A ^a   Launer, L J ^a,d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b INSERM   (France)

^c MAX PLANCK INSTITUTE   (Germany)

^d NATIONAL INSTITUTE ON AGING   (United States)

^e NONE

Author keywords

Epidemiology; Institutionalization Elderly; Mortality; PD; Prognosis

Indexed keywords

AGED; ARTICLE; DATA ANALYSIS; EUROPE; FEMALE; HUMAN; INSTITUTIONALIZATION; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT;

AGE FACTORS; AGED; AGED, 80 AND OVER; COHORT STUDIES; COST OF ILLNESS; EUROPE; FEMALE; HUMANS; INSTITUTIONALIZATION; MALE; MIDDLE AGED; PARKINSON DISEASE; PROGNOSIS; RISK; SEX FACTORS; SURVIVAL ANALYSIS;

EID: 0034643847     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Morens DM, Davis JW, Grandinetti A, Ross GW, Popper JS, White LR. Epidemiologic observations on Parkinson's disease: incidence and mortality in a prospective study of middle-aged men. Neurology 1996;46:1044-1050.
2. Bennett DA, Beckett LA, Murray AM, et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996;334:71-76.
3. Ebmeier KP, Calder SA, Crawford JR, Stewart L, Besson JA, Mutch WJ. Parkinson's disease in Aberdeen: survival after 3.5 years. Acta Neurol Scand 1990;81:294-299.
4. Louis ED, Marder K, Cote L, Tang M, Mayeux R. Mortality from Parkinson disease. Arch Neurol 1997;54:260-264.
5. Rajput AH, Offord KP, Beard CM, Kurland LT. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol 1984;16:278-282.
6. Gorell JM, Johnson CC, Rybicki BA. Parkinson's disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990. Neurology 1994;44:1865-1868.
7. Raschetti R, Spila Alegiani S, Vanacore N, Ancona C, Meco G. Mortality in a population-based cohort of patients treated with antiparkinsonian drugs. Acta Neurol Scand 1998;97:20-26.
8. Wermuth L, Stenager EN, Stenager E, Boldsen J. Mortality in patients with Parkinson's disease. Acta Neurol Scand 1995;92: 55-58.
9. Morgante L, Rocca WA, Di Rosa AE, et al. Prevalence of Parkinson's disease and other types of parkinsonism: a door-to-door survey in three Sicilian municipalities. The Sicilian Neuro-Epidemiologic Study (SNES) Group. Neurology 1992; 42:1901-1907.
10. Anderson DW, Schoenberg BS, Haerer AF. Prevalence surveys of neurologic disorders: methodologic implications of the Copiah County Study. J Clin Epidemiol 1988;41:339-345.
11. Larsen JP. Parkinson's disease as community health problem: study in Norwegian nursing homes. The Norwegian Study Group of Parkinson's Disease in the Elderly. BMJ 1991;303: 741-743.
12. Moghal S, Rajput AH, Meleth R, D'Arcy C, Rajput R. Prevalence of movement disorders in institutionalized elderly. Neuroepidemiology 1995;14:297-300.
13. Mitchell SL, Kiely DK, Kiel DP, Lipsitz LA. The epidemiology, clinical characteristics, and natural history of older nursing home residents with a diagnosis of Parkinson's disease. J Am Geriatr Soc 1996;44:394-399.
14. Trenkwalder C, Schwarz J, Gebhard J, et al. Starnberg trial on epidemiology of parkinsonism and hypertension in the elderly. Arch Neurol 1995;52:1017-1022.
15. de Rijk MC, Breteler MM, Graveland GA, et al. Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. Neurology 1995;45:2143-2146.
16. Tison F, Dartigues JF, Zuber M, Alperovitch A, Henry P. Prevalence of Parkinson's disease in the elderly: a population study of Gironde, France. Acta Neurol Scand 1994;90:111-115.
17. Fratiglioni L, Viitanen M, Backman L, Sandman PO, Winblad B. Occurrence of dementia in advanced age: the study design of the Kungsholmen Project. Neuroepidemiology 1992;11:29-36.
18. Maggi S, Zucchetto M, Grigoletto F, et al. The Italian Longitudinal Study on Aging (ILSA): design and methods. Aging Clin Exp Res 1994;6:464-473.
19. de Rijk MC, Launer LJ, Berger K, et al. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurology 2000;54(suppl 5):S21-S23.
20. Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. An examination of male-female differences in progression and mortality of Parkinson's disease. Neurology 1990;40:763-766.
21. Lilienfeld DE, Chan E, Ehland J, et al. Two decades of increasing mortality from Parkinson's disease among the US elderly. Arch Neurol 1990;47:731-734.
22. Chio A, Magnani C, Tolardo G, Schiffer D. Parkinson's disease mortality in Italy, 1951 through 1987. Analysis of an increasing trend. Arch Neurol 1993;50:149-153.
23. Clarke CE. Does levodopa therapy delay death in Parkinson's disease? A review of the evidence. Mov Disord 1995;10:250-256.
24. Scigliano G, Musicco M, Soliveri P, et al. Mortality associated with early and late levodopa therapy initiation in Parkinson's disease. Neurology 1990;40:265-269.
25. Sayler ME, Street JS, Bosomworth JC, Potvin JH, Kotsanos JG. Analysis of mortality in pergolide-treated patients with Parkinson's disease. Neuroepidemiology 1996;15:26-32.
26. Uitti RJ, Ahlskog JE, Maraganore DM, et al. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project. Neurology 1993;43:1918-1926.